KPI-121 1% for Pain and Inflammation in Ocular Surgery

References

• Sajnani R , RaiaS , GibbonsAet al. Epidemiology of persistent post-surgical pain manifesting as dry eye-like symptoms after cataract surgery. Cornea37(12), 1535 (2018).
   PubMed Web of Science ®Google Scholar
• De Maria M , IannettaD , CiminoL , CoassinM , FontanaL. Measuring anterior chamber inflammation after cataract surgery: a review of the literature focusing on the correlation with cystoid macular edema. Clin. Ophthalmol.14, 41 (2020).
   PubMed Web of Science ®Google Scholar
• Salinger C , GaynesBI , RajpalRK. Innovations in topical ocular corticosteroid therapy for the management of postoperative ocular inflammation and pain. Am. J. Managed Care.25(12), S215–S226 (2019).
   PubMedGoogle Scholar
• Olson RJ , Braga-MeleR , ChenSHet al. Cataract in the adult eye Preferred Practice Pattern®. Ophthalmol.124(2), P1–P119 (2017).
   PubMed Web of Science ®Google Scholar
• Chuck RS , JacobsDS , LeeJKet al. Refractive errors & refractive surgery Preferred Practice Pattern®. Ophthalmol.125(1), P1–P104 (2018).
   PubMed Web of Science ®Google Scholar
• Sheppard JD , ComstockTL , CavetME. Impact of the topical ophthalmic corticosteroid loteprednol etabonate on intraocular pressure. Adv. Ther.33(4), 532–552 (2016).
   PubMed Web of Science ®Google Scholar
• Amon M , BusinM. Loteprednol etabonate ophthalmic suspension 0.5 %: efficacy and safety for postoperative anti-inflammatory use. Int. Ophthalmol.32(5), 507–517 (2012).
   PubMedGoogle Scholar
• Burke JE , DennisEA. Phospholipase A2 structure/function, mechanism, and signaling. J. Lipid Res.50(Suppl.), S237–S242 (2009).
   PubMed Web of Science ®Google Scholar
• Ramamoorthy A , CidlowskiJA. Corticosteroids-mechanisms of action in health and disease. Rheum. Dis. Clin. North Am.42(10), 15–31 (2016).
   PubMedGoogle Scholar
• De Oliveira A , RosowskiEE , HuttenlocherA. Neutrophil migration in infection and wound repair: going forward in reverse. Nat. Rev. Immunol.16(6), 378–391 (2016).
   PubMed Web of Science ®Google Scholar
• Youssef J , NovosadSA , WinthropKL. Infection risk and safety of corticosteroid use. Rheum. Dis. Clin. North Am.42(1), 157–76, ix-x (2016).
   PubMed Web of Science ®Google Scholar
• Stewart R , HorwitzB , HowesJ , NovackGD , HartK. Double-masked, placebo-controlled evaluation of loteprednol etabonate 0.5% for postoperative inflammation. Loteprednol Etabonate Post-operative Inflammation Study Group 1. J. Cataract Refract. Surg.24(11), 1480–1489 (1998).
   PubMed Web of Science ®Google Scholar
• Grigorian RA , ShahA , GuoA. Comparison of loteprednol etabonate 0.5% (Lotemax) to prednisolone acetate 1% (Falcon) for inflammation treatment following cataract surgery. Invest. Ophthalmol. Vis. Sci.48(13), 1065 (2007).
   Google Scholar
• Loteprednol Etabonate Postoperative Inflammation Study Group . A double-masked, placebo-controlled evaluation of 0.5% loteprednol etabonate in the treatment of postoperative inflammation. Ophthalmol.105(9), 1780–1786 (1998).
   PubMed Web of Science ®Google Scholar
• INVELTYS prescribing information. Kala Pharmaceuticals, Inc (2020). https://inveltys.com/pdf/inveltys-prescribing-information.pdf
   Google Scholar
• Kim T , SallK , HollandEJ , BrazzellRK , CoultasS , GuptaPK. Safety and efficacy of twice daily administration of KPI-121 1% for ocular inflammation and pain following cataract surgery. Clin. Ophthalmol.13, 69–86 (2019).
   PubMed Web of Science ®Google Scholar
• Comstock TL , PaternoMR , SinghA , ErbT , DavisE. Safety and efficacy of loteprednol etabonate ophthalmic ointment 0.5% for the treatment of inflammation and pain following cataract surgery. Clin. Ophthalmol.5, 177–186 (2011).
   PubMedGoogle Scholar
• Fong R , LeitritzM , Siou-MermetR , ErbT. Loteprednol etabonate gel 0.5% for postoperative pain and inflammation after cataract surgery: results of a multicenter trial. Clin. Ophthalmol.26, 1113–1124 (2012).
   Google Scholar
• Holzer MP , SolomonKD , SandovalHP , VromanDT. Comparison of ketorolac tromethamine 0.5% and loteprednol etabonate 0.5% for inflammation after phacoemulsification: prospective randomized double-masked study. J. Cataract Refract. Surg.28(1), 93–99 (2002).
   PubMed Web of Science ®Google Scholar
• Lane SS , HollandEJ. Loteprednol etabonate 0.5% versus prednisolone acetate 1.0% for the treatment of inflammation after cataract surgery. J. Cataract Refract. Surg.39(2), 168–173 (2013).
   PubMed Web of Science ®Google Scholar
• Rajpal RK , FongR , ComstockTL. Loteprednol etabonate ophthalmic gel 0.5% following cataract surgery: integrated analysis of two clinical studies. Adv. Ther.30(10), 907–923 (2013).
   PubMed Web of Science ®Google Scholar
• Stewart R , HorwitzB , HowesJ , NovackGD , HartK. Double-masked, placebo-controlled evaluation of loteprednol etabonate 0.5 for postoperative inflammation. J. Cataract Refract. Surg.24(11), 1480–1489 (1998).
   PubMed Web of Science ®Google Scholar
• Comstock TL , SheppardJD. Loteprednol etabonate for inflammatory conditions of the anterior segment of the eye: twenty years of clinical experience with a retrometabolically designed corticosteroid. Expert Opin. Pharmacother.19(4), 337–353 (2018).
   PubMed Web of Science ®Google Scholar
• Schopf L , EnlowE , PopovA , BourassaJ , ChenH. Ocular pharmacokinetics of a novel loteprednol etabonate 0.4% ophthalmic formulation. Ophthalmol. Ther.3(1–2), 63–72 (2014).
   PubMedGoogle Scholar
• King-Smith PE , FinkBA , FogtN , NicholsKK , HillRM , WilsonGS. The thickness of the human precorneal tear film: evidence from reflection spectra. Invest. Ophthalmol. Vis. Sci.41(11), 3348–3359 (2000).
   PubMed Web of Science ®Google Scholar
• Prydal JI , CampbellFW. Study of precorneal tear film thickness and structure by interferometry and confocal microscopy. Invest. Ophthalmol. Vis. Sci.33(6), 1996–2005 (1992).
   PubMed Web of Science ®Google Scholar
• Prydal JI , ArtalP , WoonH , CampbellFW. Study of human precorneal tear film thickness and structure using laser interferometry. Invest. Ophthalmol. Vis. Sci.33(6), 2006–2011 (1992).
   PubMed Web of Science ®Google Scholar
• Mantelli F , ArgüesoP. Functions of ocular surface mucins in health and disease. Curr. Opin. Allergy Clin. Immunol.8(5), 477–483 (2008).
   PubMed Web of Science ®Google Scholar
• Olmsted SS , PadgettJL , YudinAI , WhaleyKJ , MoenchTR , ConeRA. Diffusion of macromolecules and virus-like particles in human cervical mucus. Biophys. J.81(4), 1930–1937 (2001).
   PubMed Web of Science ®Google Scholar
• Sigurdsson HH , KirchJ , LehrC-M. Mucus as a barrier to lipophilic drugs. Int. J. Pharm.453(1), 56–64 (2013).
   PubMed Web of Science ®Google Scholar
• Lotemax SM , Package insert. Bausch+Lomb, NJ, USA (2019).
   Google Scholar
• Bausch + Lomb . Press release. Bausch + Lomb announces FDA approval of Lotemax SM (loteprednol etabonate ophthalmic gel) 0.38% for the treatment of postoperative inflammation and pain following ocular surgery. Designed with SM technology for efficient penetration at a low preservative (BAK) level. https://www.bausch.com/our-company/recent-news/artmid/11336/articleid/508/2252019-monday
   Google Scholar
• Kala Pharmaceutical . Kala Pharmaceuticals announces FDA approval of INVELTYS for the treatment of post-operative inflammation and pain following ocular surgery. Press release. (2018). http://investors.kalarx.com/node/7301/pdf
   Google Scholar
• Samir A , BodorN , ImaiT. Identification of esterase involved in the metabolism of two corticosteroid soft drugs. Biochem. Pharmacol.127, 82–89 (2017).
   PubMed Web of Science ®Google Scholar
• Popov A . Mucus-penetrating particles and the role of ocular mucus as a barrier to micro- and nanosuspensions. J. Ocul. Pharmacol. Ther.36(6), 366–375 (2000).
   Google Scholar